COMUNICADO: Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clini

Actualizado 15/08/2011 18:25:38 CET

INDIANAPOLIS and TOKYO, August 15, 2011 /PRNewswire/ --


Analysis evaluated efficacy and safety among three patient
sub-groups

A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study - those identified as the "core clinical cohort" population - showed that treatment with prasugrel (in combination with aspirin) was associated with a 26 percent relative risk reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke, compared to treatment with clopidogrel (8.3 percent vs. 11.0 percent, respectively, p<0.0001).(1) This corresponds to a 2.7 percent absolute risk reduction for patients treated with prasugrel. The results of this analysis, which also examined clinical outcomes in two other cohorts of patients who were treated for acute coronary syndromes (ACS) and underwent angioplasty with stenting, will help inform appropriate physician prescribing of prasugrel. These data were recently published online in the American Journal of Cardiology.(1)

For this analysis, investigators analyzed three patient clinical cohorts:


- The core clinical cohort: Patients who were under 75 years
of age, weighed 60 kg or more and who had no prior history of stroke or
transient ischemic attack (TIA). This group (n=10,804, 79 percent of all
study subjects) excluded those patients considered to be at a higher
risk for bleeding by the U.S. Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) in their regulatory approval of
prasugrel and as outlined in prescribing labels for prasugrel tablets in
these regions.(1)
- The non-core cohort: Patients 75 years of age or older or
patients who weighed less than 60 kg, but without known prior stroke or
TIA (n=2,149; 16 percent of study participants).(1) The use of prasugrel
in patients greater than or equal to 75 years is generally not
recommended. If, after a careful individual benefit/risk evaluation by
the prescribing physician, treatment is deemed necessary in the patient
age group greater than or equal to 75 years, then following a 60 mg
loading dose, a reduced maintenance dose of 5 mg should be
prescribed.(2)
- The third group were patients with a self-reported or known
history of stroke or TIA prior to enrollment (n=518; 4 percent of study
participants). Prasugrel is contraindicated in such patients.(1)
- Patients without known prior stroke but with missing baseline
weight data were excluded from the analysis as it could not be
determined to which final cohort they should be assigned to (n= 137; 1
percent of study participants).(1)

In the core clinical cohort, there were higher bleeding rates in prasugrel patients compared to clopidogrel patients.(1) Appropriate prescribing may help minimize a bleeding risk. Based on the post hoc analysis reported in this paper, in patients in the TRITON-TIMI 38 study who were younger than 75, heavier than 60 kg and with no prior stroke, the difference in the rates of certain types of bleeding (known as non-CABG TIMI major bleeding) was reduced, without adversely impacting the efficacy of prasugrel versus clopidogrel.

Relative bleeding rates were similar across the core and "non-core" groups. In the core group, the rate of TIMI major bleeding was 1.9 percent in prasugrel patients compared to 1.5 percent in clopidogrel patients, corresponding to a 0.4 percent absolute increase and a 24 percent relative increase in prasugrel patients (p= 0.17).(1) In the non-core group, the rate of TIMI major bleeding was 4.1 percent in prasugrel patients compared to 3.4 percent in clopidogrel patients, corresponding to a 0.7 percent absolute increase and a 23 percent relative increase in prasugrel patients (p= 0.40).(1) In both cases findings were not statistically significant.

The rate of TIMI major or minor bleeding was statistically significantly greater with prasugrel than clopidogrel in the core group (3.9 percent vs. 3.0 percent respectively, p=0.033), but not in the non-core group (9.8 percent prasugrel vs. 7.5 percent clopidogrel, p=0.08), although the relative increase in bleeding within these groups were similar.(1)

"This analysis showed that the use of prasugrel in a clinically identifiable population of ACS patients undergoing PCI in the TRITON-TIMI 38 trial significantly improved cardiovascular outcomes," said Stephen D Wiviott, M.D., at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, and lead author of the paper.(1)

The analysis found that in greater than or equal to 75 year old and low body weight (<60kg) patients (the non-core cohort), event rates were high in both treatment arms (15.3 vs. 16.3 percent, p=0.61, HR=0.94) compared to the core cohort group.(1) Patients taking prasugrel in the third group (described above) had non-favorable results with regard to both efficacy and safety compared to clopidogrel, with a higher rate of primary efficacy events (19.1 percent vs. 14.4 percent, p=0.15) driven by an increase in stroke and a higher rate of bleeding, including more intracranial hemorrhage (2.3 percent vs. 0 percent, p=0.02).(1) Prasugrel is contraindicated in patients who have had a prior transient ischemic attack (TIA) or stroke.

The TRITON-TIMI 38 trial was sponsored by Daiichi Sankyo Co., Ltd. and Eli Lilly and Company.

Study Methodology

TRITON-TIMI 38 was a head-to-head study comparing prasugrel (60-mg loading dose [LD], followed by a 10-mg once-daily maintenance dose) plus aspirin (ASA) with clopidogrel (300-mg LD, followed by a 75-mg once-daily maintenance dose) plus ASA in 13,608 patients with ACS managed with percutaneous coronary intervention (PCI), a procedure to open blockages in heart arteries, including the use of coronary stenting. The median duration of study treatment was 14.5 months.(3)

The primary endpoint of the study was the combined incidence of cardiovascular death, non-fatal heart attack or non-fatal stroke in patients followed for 6 - 15 months following PCI. The study showed that prasugrel taken with ASA had a 19 percent relative risk reduction of the combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke versus clopidogrel taken with ASA (9.9 percent vs. 12.1 percent respectively, p<0.001).(3) This corresponds to a 2.2 percent absolute risk reduction for ACS patients treated with prasugrel. In TRITON-TIMI 38, patients treated with prasugrel also experienced a 50 percent relative risk reduction (corresponding to 1.1 percent absolute risk reduction) in stent-related clots when compared with clopidogrel, regardless of stent type (1.1 percent vs. 2.4 percent respectively, p<0.001).(3) In TRITON, the risk of non-coronary artery bypass graft (non-CABG) major bleeding, including fatal bleeding, was higher with prasugrel (2.4 percent incidence) compared with clopidogrel (1.8 percent incidence) (p=0.03). The rate of TIMI major or minor bleeding was significantly greater with prasugrel than clopidogrel (5.0 percent vs. 3.8 percent respectively, p=0.002). The risk of coronary artery bypass graft (CABG) major bleeding, including fatal bleeding, was higher with prasugrel (13.4 percent incidence) than clopidogrel (3.2 percent incidence) (p<0.001).(3) In TRITON-TIMI 38, the loading dose of clopidogrel was delayed relative to the placebo-controlled trials that supported its approval for ACS.

(CONTINUA)

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación